An open label clinical pilot study with local injection of human antibody (HuMax-Inflam) for the treatment of inflammatory psoriasis.

Trial Profile

An open label clinical pilot study with local injection of human antibody (HuMax-Inflam) for the treatment of inflammatory psoriasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2012

At a glance

  • Drugs HuMax IL8 (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Genmab
  • Most Recent Events

    • 28 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top